<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2059">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938665</url>
  </required_header>
  <id_info>
    <org_study_id>SRP-1418</org_study_id>
    <nct_id>NCT00938665</nct_id>
  </id_info>
  <brief_title>Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.</brief_title>
  <acronym>COGNISION™</acronym>
  <official_title>Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuronetrix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuronetrix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is designed to evaluate the performance of the COGNISION™ System as a tool&#xD;
      to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.&#xD;
      The design of this study is guided by two overriding factors: 1) to optimize the performance&#xD;
      of the event related potentials (ERP) classifiers, the subjects making up the training sets&#xD;
      must be well characterized as to their clinical diagnosis, and 2) all ERP tests must be&#xD;
      performed and reproduced in real-world clinical settings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be :&#xD;
&#xD;
      A. Multi-Center Study:&#xD;
&#xD;
      primary goal of this study will be to evaluate the COGNISION™ Platform across multiple study&#xD;
      locations. This will demonstrate an ability to perform tests, collect data, and generate&#xD;
      classifications irrespective of variations in testing locations and personnel.&#xD;
&#xD;
        1. 5-8 study sites will be selected with each site being a recognized NIH Center of&#xD;
           Excellence for Alzheimer's disease or other nationally recognized Alzheimer's disease&#xD;
           research center.&#xD;
&#xD;
        2. Each site will evaluate up to 60 subjects evenly divided between AD patients and&#xD;
           age-matched controls (while the prevalence of AD is approximately 2% in the general&#xD;
           population, the ratio of AD to normal among those who visit a clinic for memory or&#xD;
           cognitive related issues is between 50-60%).&#xD;
&#xD;
        3. Each site will follow the same testing protocols.&#xD;
&#xD;
        4. All test data will be uploaded to the online COGNISION™ database server.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Electrophysiological markers of cognitive status</measure>
    <time_frame>Markers are collected at study visit</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">204</enrollment>
  <condition>Memory Disorders</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>AD Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>COGNISION™ System</intervention_name>
    <description>30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.</description>
    <arm_group_label>AD Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. These lab tests will be performed from a standard blood draw:&#xD;
&#xD;
             1. B12&#xD;
&#xD;
             2. TSH&#xD;
&#xD;
             3. CRP&#xD;
&#xD;
             4. ALT&#xD;
&#xD;
             5. HGB&#xD;
&#xD;
             6. Hgb1AC&#xD;
&#xD;
             7. T4&#xD;
&#xD;
             8. Na&#xD;
&#xD;
             9. K&#xD;
&#xD;
            10. Cl&#xD;
&#xD;
            11. CO2&#xD;
&#xD;
            12. ApoE&#xD;
&#xD;
            13. Platelet Count&#xD;
&#xD;
            14. INR&#xD;
&#xD;
            15. PT&#xD;
&#xD;
        2. MRI- INCLUDING VOLUMETRY&#xD;
&#xD;
        3. CSF 5ML (Optional)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects between 60 and 90 years old meeting DSM-IV criteria for dementia of the&#xD;
        Alzheimer's type and NINCDS-ADRDA criteria for probable AD will be recruited in the AD&#xD;
        cohort. Matched cognitively healthy volunteers will be recruited for the Control group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        AD Cohort:&#xD;
&#xD;
        Subjects between 60 and 90 years old meeting NINCDS-ADRDA criteria for probable AD2 and&#xD;
        DSM-IV criteria for dementia of the Alzheimer's type3 will be recruited in the AD cohort&#xD;
        (MMSE ≥21, ≤26).&#xD;
&#xD;
        Memory complaint by subject and/or study partner SRP-1418 N Page: 8 of 26&#xD;
&#xD;
        Abnormal memory function score on Logical Memory II subscale (Delayed Paragraph Recall)&#xD;
        from the Wechsler Memory Scale - Revised (adjusted for education. Maximum score is 25):&#xD;
&#xD;
        i. &lt; 10 for 16 or more years of education ii. &lt; 6 for 8-15 years of education iii. &lt; 4 for&#xD;
        0-7 years of education Clinical Dementia Rating (CDR) = 0.5, 1.0 or 2.0 Modified Hachinski&#xD;
        Ischemic Scale (HIS) ≤ 4 Geriatric Depression Scale (GDS) &lt; 6 For subjects that decide to&#xD;
        provide a CSF sample: Platelet count ≥ 100,000/μL, Prothrombin Time (PT) = 11 to 16&#xD;
        seconds, International Normalized Ratio = 0.8 to 1.2 Study partner or caregiver to&#xD;
        accompany subject to all scheduled visits Fluent in English Adequate visual acuity to allow&#xD;
        neuropsychological testing Adequate auditory acuity to allow neuropsychological and ERP&#xD;
        testing Good general health with no additional diseases expected to interfere with the&#xD;
        study Willing to undergo neuroimaging and provide blood. The subject may optionally provide&#xD;
        a CSF sample by lumbar puncture.&#xD;
&#xD;
        Normal Controls:&#xD;
&#xD;
        Healthy subjects matched for age, gender, and education level will be recruited as normal&#xD;
        controls (MMSE ≥ 27).&#xD;
&#xD;
        Normal memory function will be documented by scoring at specific cutoffs on the&#xD;
&#xD;
        Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale -&#xD;
        Revised:&#xD;
&#xD;
        i. ≥ 10 for 16 or more years of education ii. ≥ 6 for 8-15 years of education iii. ≥ 4 for&#xD;
        0-7 years of education Study partner or caregiver Fluent in English Adequate visual acuity&#xD;
        to allow neuropsychological testing Adequate auditory acuity to allow neuropsychological&#xD;
        and ERP testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        AD Cohort:&#xD;
&#xD;
        Severe or unstable forms of diabetes, heart disease, HIV, drug or alcohol abuse, etc.&#xD;
        including severe AD: MMSE ≤20 Platelet count &lt; 100,000/μL, Prothrombin Time (PT) &gt; 16&#xD;
        seconds, International Normalized Ratio &gt; 1.2 (for subjects that choose to provide a CSF&#xD;
        sample by lumbar puncture).&#xD;
&#xD;
        Medical or psychiatric disorders that might complicate the assessment of dementia (i.e.,&#xD;
        mental retardation, alcohol abuse, drug abuse, HIV) A disability that may prevent the&#xD;
        subject from completing all study requirements (e.g., blindness, deafness, language&#xD;
        difficulty) Recent intake of drugs known to cause major organ system toxicity or CNS&#xD;
        alteration (e.g. sedation) Diseases of the dementia type other than AD (i.e., vascular&#xD;
        dementia, frontotemporal dementia, Lewy Body Disease, Huntington's disease) Presence of&#xD;
        non-MRI compatible implants/devices Prohibited Medications: Warfarin or other&#xD;
        anticoagulants (for subjects that choose to provide a CSF sample by lumbar puncture),&#xD;
        investigational agents.&#xD;
&#xD;
        Normal Controls:&#xD;
&#xD;
        Severe or unstable forms of diabetes, heart disease, HIV, drug or alcohol abuse, etc.&#xD;
&#xD;
        A disability that may prevent the subject from completing all study requirements (e.g.,&#xD;
        blindness, deafness, language difficulty) Use of psychoactive drugs (only SSRI's are&#xD;
        allowed) Psychiatric disorders (schizophrenia, bipolar, etc.) Depression (GDS &gt; 6) Vascular&#xD;
        dementia (HIS &gt; 4) Other dementia (CDR &gt; 0)&#xD;
&#xD;
        Abnormal memory function score on Wechsler Memory Scale -Logical Memory II subscale&#xD;
        (delayed Paragraph Recall) from the Wechsler Memory Scale - Revised (the maximum score is&#xD;
        25):&#xD;
&#xD;
        I. &lt; 10 for 16 or more years of education II. &lt; 6 for 8-15 years of education III. &lt; 4 for&#xD;
        0-7 years of education&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles D Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Kentucky</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murali Doraiswamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven E Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul R Solomon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Memory Clinic, Bennington VT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley S Folley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norton Healthcare, Louisville KY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl Sadowsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premiere Research Institute, West Palm Beach FL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew E Budson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Center for Memory</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premiere Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Memory Clinic</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2009</study_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>Memory disorder</keyword>
  <keyword>dementia</keyword>
  <keyword>cognitive behavioral decline</keyword>
  <keyword>vascular dementia</keyword>
  <keyword>front temporal dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

